IRIS
IAFFALDANO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.275
AS - Asia 2.700
EU - Europa 2.660
SA - Sud America 682
Continente sconosciuto - Info sul continente non disponibili 468
AF - Africa 223
OC - Oceania 11
Totale 14.019
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.008
SG - Singapore 1.012
IT - Italia 986
CN - Cina 602
BR - Brasile 504
SE - Svezia 351
RU - Federazione Russa 331
HK - Hong Kong 324
VN - Vietnam 217
GB - Regno Unito 205
DE - Germania 190
FR - Francia 179
CA - Canada 125
BD - Bangladesh 116
CI - Costa d'Avorio 114
FI - Finlandia 109
IN - India 81
AR - Argentina 78
NL - Olanda 60
JP - Giappone 49
IQ - Iraq 44
UA - Ucraina 41
LT - Lituania 39
ID - Indonesia 38
MX - Messico 37
SA - Arabia Saudita 35
BE - Belgio 33
ZA - Sudafrica 27
EC - Ecuador 26
PL - Polonia 26
CO - Colombia 25
PK - Pakistan 25
TR - Turchia 25
PH - Filippine 23
UZ - Uzbekistan 23
AT - Austria 22
CR - Costa Rica 22
ES - Italia 22
VE - Venezuela 21
JM - Giamaica 16
TN - Tunisia 15
EG - Egitto 13
JO - Giordania 11
KE - Kenya 11
SV - El Salvador 11
CL - Cile 10
NI - Nicaragua 10
AE - Emirati Arabi Uniti 9
AU - Australia 9
HN - Honduras 9
IL - Israele 9
MA - Marocco 9
MY - Malesia 9
CZ - Repubblica Ceca 8
PR - Porto Rico 8
CW - ???statistics.table.value.countryCode.CW??? 7
EE - Estonia 7
IE - Irlanda 7
PY - Paraguay 7
ET - Etiopia 6
GT - Guatemala 6
IR - Iran 6
NP - Nepal 6
PT - Portogallo 6
RO - Romania 6
AL - Albania 5
KZ - Kazakistan 5
SN - Senegal 5
UY - Uruguay 5
BB - Barbados 4
BO - Bolivia 4
CH - Svizzera 4
DK - Danimarca 4
DZ - Algeria 4
GP - Guadalupe 4
HU - Ungheria 4
KG - Kirghizistan 4
LB - Libano 4
PA - Panama 4
PS - Palestinian Territory 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
EU - Europa 3
LV - Lettonia 3
MZ - Mozambico 3
OM - Oman 3
A1 - Anonimo 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
RW - Ruanda 2
SC - Seychelles 2
SX - ???statistics.table.value.countryCode.SX??? 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BJ - Benin 1
Totale 13.535
Salva come PNG Salva come JPEG
Città #
Ashburn 854
Fairfield 616
Singapore 512
San Jose 473
Chandler 432
Woodbridge 378
Dallas 331
Hong Kong 324
Milan 288
Houston 281
Nyköping 270
Seattle 258
Ann Arbor 240
Cambridge 213
Beijing 180
Wilmington 176
Council Bluffs 161
Los Angeles 133
Abidjan 114
New York 112
Lauterbourg 99
Lawrence 81
Jacksonville 77
Rome 74
Roxbury 71
Bari 70
Santa Clara 70
Helsinki 69
Ho Chi Minh City 69
Boardman 66
Brooklyn 62
São Paulo 61
Columbus 56
Chicago 54
Buffalo 51
Des Moines 49
Tokyo 44
Munich 42
Hanoi 41
Nanjing 41
Princeton 38
London 37
Toronto 37
Moscow 36
Frankfurt am Main 35
North Bergen 34
Amsterdam 33
Brussels 33
Nuremberg 33
Orem 32
Falkenstein 31
Inglewood 30
Vilnius 29
San Diego 27
Atlanta 26
Guangzhou 26
Montreal 25
Figino 23
Phoenix 23
Paris 21
Jakarta 20
Norwalk 20
San José 20
Naples 19
Rio de Janeiro 18
Salt Lake City 18
Warsaw 18
Shanghai 17
Jeddah 16
Johannesburg 16
Baghdad 15
Poplar 15
San Francisco 15
Turin 15
Tashkent 14
Dong Ket 13
Stockholm 13
Tianjin 13
Bologna 12
Denver 12
Dhaka 12
Miami 12
Quito 12
Bisceglie 11
Buenos Aires 11
Chennai 11
Haiphong 11
Lahore 11
San Salvador 11
Shenyang 11
Taranto 11
Washington 11
Amman 10
Boston 10
Cagliari 10
Manchester 10
Nanchang 10
Vienna 10
Da Nang 9
Dearborn 9
Totale 8.734
Salva come PNG Salva come JPEG
Nome #
Signs and symptoms of COVID-19 in patients with multiple sclerosis 249
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 238
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 223
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 215
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 204
Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial 203
Sclerosi Multipla e Lavoro: dati preliminari 195
Prognostic indicators in pediatric clinically isolated syndrome 195
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 193
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 190
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 189
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 188
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 180
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 176
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 174
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 170
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 168
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 164
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 161
Multiple sclerosis registries in Europe – An updated mapping survey 160
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 158
Treatment decisions in multiple sclerosis-insights from real-world observational studies 156
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 153
Multiple Sclerosis Progression and Relapse Activity in Children 150
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 149
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 145
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 144
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis 143
Treating multiple sclerosis with natalizumab. 140
Dengue fever in a multiple sclerosis patient taking Ocrelizumab 140
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 139
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 138
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 135
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis 134
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 134
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 132
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 131
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 130
Geographical variations in sex ratio trends over time in multiple sclerosis. 128
Emotional and neutral verbal memory impairment in Multiple Sclerosis 128
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 128
Safety profile of Tysabri: international risk management plan 127
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 127
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 127
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 126
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 126
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 125
Low serum urate levels are associated to female gender in multiple sclerosis patients. 125
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 125
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 124
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients 122
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 121
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 120
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study 119
A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis 119
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 118
Disability assessment using Google Maps 118
Predictors and dynamics of postpartum relapses in women with multiple sclerosis. 117
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 116
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register 115
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients 113
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 113
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 112
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 112
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries 111
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 109
null 109
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 109
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network 105
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 104
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 102
Anxiety state affects information processing speed in patients with multiple sclerosis 102
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 99
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis 98
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 97
Assessing long-term effectiveness of MS treatment - a matter of debate 96
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 95
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study 94
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network 93
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 93
Natalizumab reduces serum pro-angiogenic activity in MS patients 91
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series 89
Big Multiple Sclerosis Data network: an international registry research network 88
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA) 87
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 87
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis 85
Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate 83
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 83
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 82
Risk of Getting COVID-19 in People With Multiple Sclerosis 82
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 80
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register 78
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 77
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 77
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry 76
null 73
Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender 73
Interrogating large multiple sclerosis registries and databases: what information can be gained? 71
Real-life impact of early interferonbeta therapy in relapsing multiple sclerosis 70
null 68
Totale 12.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.048
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.048
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022577 0 0 0 0 49 87 34 44 51 48 117 147
2022/20231.102 158 170 88 87 128 131 20 120 151 4 26 19
2023/2024442 41 54 29 24 41 95 16 25 6 30 11 70
2024/20252.094 149 38 126 74 68 153 223 187 126 116 291 543
2025/20265.336 653 362 478 473 540 381 447 192 545 506 182 577
2026/20271.443 184 216 306 700 37 0 0 0 0 0 0 0
Totale 14.019